ERBB2 and cancer: Regarding EV lncRNAs, Dong et al. [130] have previously shown that isolated EVs from HER2-positive advancedbreast cancer patients who were nonresponders to trastuzumab therapy contained more lncRNASNHG14 than EVs from responders.